Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04740034 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04740034 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 42 participants.
The verdict
NCT04740034, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of AMG 340, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer (mCRPC) who have received 2 or more prior lines of therapy. The study consists of 2 parts, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B). Once the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified in Arm A, Arm B will be initiated to further characterize the safety, tolerability and pharmacokinetic (PK) profile of the MTD/RP2D dose of AMG 340 monotherapy in subjects with mCRPC.
Interventions
- DRUG AMG 340
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04740034
The ClinicalTrials.gov registry entry for NCT04740034 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 340 is the first listed.
NCT04740034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04740034 about?
NCT04740034 is a clinical study titled "A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma". This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of AMG 340, a PSMA x CD3 T-cell engaging bispecific antibody, in subjects with metastatic castrate-resistant prostate cancer (mCRPC) who have received 2 or more prior lines of therapy. The study co...
What is the current status of trial NCT04740034?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-04-29. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT04740034?
The interventions under investigation include: AMG 340 (DRUG).
Who is sponsoring clinical trial NCT04740034?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.